Presentation AHA 2016

The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I)

Presenter: Michael Gibson

November 15, 2016

REGISTER for free or LOG IN to view this content

AEGIS-I Trial: The Safety and Tolerability of CSL112

Coronary

ACS/AMI

Presentation

AHA 2016

Up Next

Presentation

2016 TCTMD Heart Team Survey

April 13, 2016

More slides +

Presentation

Efficacy and Safety of the Absorb Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus: Absorb Diabetic Substudy

Presenter: D. Kereiakes

December 23, 2016

Presentation

Apixaban in Patients With Atrial Fibrillation After TAVR

Presenter: J. Seeger

January 03, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.